- Home
- BOLT
as 05-14-2025 4:00pm EST
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 16.8M | IPO Year: | 2021 |
| Target Price: | $1.00 | AVG Volume (30 days): | 103.8K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $1.33 | Next Earning Date: | 05-12-2025 |
| Revenue: | $3,638,000 | Revenue Growth: | -67.87% |
| Revenue Growth (this year): | -62.29% | Revenue Growth (next year): | 77.48% |
Stock Insider Trading Activity of Bolt Biotherapeutics Inc. (BOLT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Quinn William P. | BOLT | President, CEO and CFO | May 1 '25 | Buy | $0.57 | 5,000 | $2,834.75 | 41,272 |
Latest Bolt Biotherapeutics Inc. News
BOLT Breaking Stock News: Dive into BOLT Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
2 days ago
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot
GlobeNewswire
2 days ago
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
TipRanks
4 days ago
Biotech Alert: Searches spiking for these stocks today
GlobeNewswire
7 days ago
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
GlobeNewswire
14 days ago
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
GlobeNewswire
19 days ago
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
GlobeNewswire
2 months ago
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Compare BOLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BOLT Bolt Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.